GFPD joins with 125 other patient advocacy groups urging congress to support critical rare disease priorities

The GFPD is proud to be one of 126 organizations, representing or treating patients impacted by rare diseases and other acute or chronic health conditions, urging Congress to include a full five-year reauthorization of the programs listed in Section F, Title V of H.R. 6833 (‘Title V programs’), of the Continuing Appropriations and Ukraine Supplemental Appropriations Act of 2023 and to include important reforms to the Federal Food, Drug and Cosmetic Act (FFDCA) in any end-of-year legislative package under development. See the letter below from the GFPD and our partners.